|  |  |  |  |  |  |  |  | Genotype | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
First author | Year | Country | Population | Gende (male %) | Age | Follow-up period | Treatment protocal | Lipid | CC | CT | TT | HWE |
Fiegenbaum [10] | 2005 | Brazil | Hypercholesterolemic patients | 25.3 | 59.2 ± 10.7 | 6 months | simvastatin 20 mg/day | TC LDL-C HDL-C TG | 20 | 45 | 32 | 0.570 |
Hoenig [15] | 2011 | Australia | Patients recruited with CAD, ischemic stroke, or CAD risk-equivalents | 79 | 67.6 ± 10 | 6 weeks | atorvastatin 80 mg/day | TC LDL-C HDL-C TG | 15 | 42 | 41 | 0.440 |
Kajinami m [9] | 2004 | USA | Hypercholesterolemia patients | 100 | 58 ± 11 | 52 weeks | atorvastatin 10 mg/day | TC LDL-C HDL-C TG | 49 | 101 | 56 | 0.793 |
Kajinami w [9] | 2004 | USA | Hypercholesterolemia patients | 0 | 58 ± 11 | 52 weeks | atorvastatin 10 mg/day | TC LDL-C HDL-C TG | 36 | 60 | 42 | 0.130 |
Rodrigues [13] | 2005 | Brazil | Hypercholesterolemia patients | 40.6 | 59 ± 12 | 4 weeks | atorvastatin 10 mg/day | TC LDL-C HDL-C TG | 19 | 36 | 14 | 0.684 |
Rosales [12] | 2012 | Chile | Hypercholesterolemia patients | 62.7 | 56.4 ± 10.7 | 1 month | atorvastatin 10 mg/day | TC LDL-C HDL-C TG | 60 | 68 | 14 | 0.404 |
Shabana [14] | 2013 | Egypt | Hypercholesterolemia patients | 57 | 55.2 ± 9.9 | 4 weeks | atorvastatin 40 mg/day | TC LDL-C HDL-C TG | 19 | 20 | 11 | 0.206 |
Salacka [11] | 2014 | Poland | NA | 43 | NA | 2-83weeks | atorvastatin 10–20 mg/day, simvastatin 20–40 mg/day | TC HDL-C TG | 25 | 65 | 40 | 0.878 |